Connect with us

Hi, what are you looking for?


Buy the recent dip in Biotech stocks: Jefferies

“XBI” – the SPDR S&P Biotech ETF down more than 10% over the past three weeks is an opportunity to “buy”, says Michael Yee. He’s a Managing Director at Jefferies.

Why is he bullish on the biotech stocks?

Yee sees several tailwinds that will help the biotech stocks move up not just in the balance of 2022 but in the next year as well. Speaking with CNBC’s Carl Quintanilla on “Closing Bell”, he said:

I really like the recent rally off the bottom. It’s an important data point that we’ve had. Bunch of positive clinical data sets, a bunch of financings, a bunch of good news. I think we’re headed higher into the end of the year and then in 2023.

At the current valuation (a little over the pandemic low), he added, the Inflation Reduction Act and the consequent restrictions on drug pricing is not very likely to be a threat for the biotech stocks.

M&A in biotech is keeping investors excited

Versus its year-to-date low, the exchange-traded fund is up more than 30% as sentiment improved in recent months on news of merger and acquisitions, which, as per Yee, will remain a tailwind moving forward.

You’ve had a bunch of deals in the past two months. Pfizer is being particularly aggressive, deploying a lot of their COVID money across the space, has got everybody excited. You’ve got Merck looking at Seattle Genetics.

J.P. Morgan is scheduled for its “41st Annual Healthcare Conference” on January 9th, 2023 in San Francisco. The Jefferies analyst expects “that” to be a catalyst for the biotech stocks as well.  

The post Buy the recent dip in Biotech stocks: Jefferies appeared first on Invezz.

Enter Your Information Below To Receive Free Trading Ideas, Latest News And Articles.

    Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

    You May Also Like


    Reprinted from the Future of Freedom Foundation President Biden’s campaign to banish (or maybe outlaw) political paranoia took a wallop last spring. In April,...


    Inflation appears to be on the decline. The Personal Consumption Expenditures Price Index (PCEPI), which is the Federal Reserve’s preferred measure of inflation, grew...

    Editor's Pick

    It’s already a cliché, but technology is rapidly improving. And for many businesses, it’s hard to catch up. However, it’s not just the average...

    Editor's Pick

    At Broadband World Forum 2022, Fibocom launched 5G module FG370 based on MediaTek T830 platform, aiming to empower the deployment of 5G FWA for...

    Disclaimer:, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2022 All Rights Reserved.